Nothing currently available kills herpes once it’s inside your body. The virus embeds itself in nerve cells, where it enters a dormant state that no medication, supplement, or immune response can fully eradicate. What antivirals can do is stop the virus from copying itself during active outbreaks, shorten healing time, and dramatically reduce how often the virus reactivates. Outside the body, herpes is fragile and dies easily on surfaces.
Why the Virus Can’t Be Eliminated
Herpes simplex virus (HSV-1 and HSV-2) works differently from infections your body can clear. After the initial infection, the virus travels along nerves and settles into clusters of nerve cells called ganglia. HSV-1 typically lodges in nerve clusters near the base of the skull, while HSV-2 prefers nerve clusters near the base of the spine. Once there, the virus inserts its genetic material into the neurons and goes quiet.
During this dormant phase, the virus produces almost no proteins that your immune system can detect. It’s essentially invisible. Your body can’t destroy the infected nerve cells without damaging your own nervous system, so the virus persists for life. Periodically, it reactivates, travels back down the nerve to the skin, and causes an outbreak or sheds silently without symptoms.
How Your Immune System Keeps It in Check
Your body does mount a strong defense, even if it can’t finish the job. Specialized immune cells called CD8+ T cells physically cluster around the nerve cells where herpes hides. These T cells remain in an activated state permanently, producing a signaling molecule called interferon-gamma that suppresses the virus whenever it tries to wake up. Remarkably, they do this without destroying the neurons themselves.
This is why outbreaks tend to become less frequent over time for many people. Your immune system gets better at catching reactivation early. It’s also why outbreaks worsen during periods of immune suppression from stress, illness, or certain medications.
What Antiviral Medications Actually Do
Prescription antivirals don’t kill herpes directly. They block the virus from replicating by mimicking one of the building blocks the virus needs to copy its DNA. When the virus grabs the fake building block and tries to incorporate it, the copying process stalls permanently. The viral DNA polymerase (the enzyme responsible for replication) becomes inactivated.
Three oral antivirals are commonly prescribed. Acyclovir is the oldest and requires more frequent dosing. Valacyclovir is a modified version that converts to acyclovir in your gut and liver but absorbs much better, so you take fewer pills. Famciclovir converts to penciclovir in the body and works through the same DNA-blocking mechanism. All three reduce outbreak severity and duration, and all three can be taken daily as suppressive therapy to prevent outbreaks from happening in the first place.
Daily suppressive therapy with valacyclovir reduces viral shedding by about 94%. That matters not just for outbreak prevention but for reducing the chance of passing the virus to a partner, since herpes can transmit even when no sores are visible.
How Well Topical Treatments Work
Topical options exist but offer modest benefits compared to oral antivirals. Docosanol 10% cream (sold as Abreva) is the only FDA-approved over-the-counter topical for cold sores. It shortens healing time by roughly 18 hours compared to no treatment. Prescription penciclovir 1% cream shortens healing by about 0.7 to 1 day, while prescription acyclovir 5% cream shaves off about half a day.
For genital herpes, topical acyclovir performs poorly. Clinical trials found it reduced only the duration of viral shedding from lesions, with no meaningful difference in healing time, pain duration, or new lesion formation. Oral antivirals are far more effective for genital outbreaks.
Do Supplements Like Lysine Work?
L-lysine is the most widely discussed natural approach, and the evidence is mixed at best. A review of available clinical trials found that doses under 1 gram per day are essentially ineffective unless combined with a low-arginine diet. One trial using 1 gram daily showed a 40% reduction in recurrences, while another found that roughly 1,250 mg daily reduced outbreaks but 624 mg did not.
At 3 grams per day, one trial found patients reported a better subjective experience, but there was no significant difference in actual healing time of active sores. The bottom line: lysine at higher doses may modestly reduce how often outbreaks occur for some people, but it does not treat active outbreaks and is not a substitute for antiviral medication.
Herpes Dies Easily Outside the Body
While herpes is stubbornly persistent inside nerve cells, it’s extremely fragile on surfaces. The virus has a lipid (fatty) envelope that breaks apart easily. Ethyl alcohol at concentrations of 60% to 80% inactivates herpes on contact, according to CDC guidelines. Standard household disinfectants, soap and water, and even brief exposure to dry air will destroy the virus. This is why herpes transmission from surfaces like toilet seats or shared towels is considered negligible. The virus requires direct skin-to-skin or mucous membrane contact to spread effectively.
How Condoms Reduce Transmission
Condoms provide significant but imperfect protection. A study of couples where one partner had HSV-2 found condoms reduced per-act transmission risk by 96% from men to women and 65% from women to men. The difference likely reflects the fact that condoms cover more of the skin surface involved in male-to-female transmission but leave more potentially shedding skin exposed when the woman is the one carrying the virus. Combining condom use with daily suppressive antiviral therapy offers the strongest protection available.
Gene Editing and Vaccine Progress
The closest thing to actually “killing” herpes inside the body is gene-editing technology. CRISPR-based approaches aim to cut the viral DNA out of infected nerve cells, which would be a true cure. So far, no CRISPR therapy has been approved for herpes treatment. One small Phase 1/2 clinical trial treated three patients with severe herpes-related eye disease using a CRISPR-based approach injected directly into the cornea. All three remained virus-free in follow-up testing over an average of 18 months with no recurrence. It’s a promising signal, but extremely early-stage and limited to eye disease so far. No study has achieved complete elimination of latent herpes genomes.
On the vaccine front, Moderna completed a Phase 1/2 trial of an mRNA-based therapeutic vaccine (mRNA-1608) for genital herpes in April 2025, enrolling 365 adults with recurrent HSV-2. Results have not yet been published. This vaccine is designed to reduce outbreaks in people already infected rather than prevent new infections. Several other vaccine candidates from other companies are in earlier stages of development.